SCIENTIFIC HIGHLIGHTS

Lipid-based Nanovesicles for Nanomedicine
14 December 2016

N. Grimaldi, F. da Silva, N.V. Segovia, L. Ferrer-Tasies, S. Sala, J. Veciana,* and N. Ventosa*, Chem. Soc. Rev., 2016, 45, 6520—6545. DOI: 10.1039/C6CS00409A

 This review presents the large plethora of lipid-based nanovescicles available nowadays, focusing on a new generation of non-liposomal L-NVs and showing their similarities and differences with respect to their ancestors (liposomes). Since the overspread of a nanomaterial to the market is also strongly dependent on the availability of technological-scale preparation methods, it also extensively review the current approaches exploited for L-NV production. The most cutting-edge approaches for their preparation based on compressed fluid (CF) technologies is highlighted since they show the potential to represent a game-change in the production of L-NVs, favoring their step from the bench to the market. Finally, this review briefly discusses L-NV applications in nanomedicine looking also for their future perspectives.

Hits: 4870
Bioactive materials for therapy and diagnosis

Lipid-based Nanovesicles for Nanomedicine



Also at ICMAB

  • Limbal Stem Cells on Bacterial Nanocellulose Carriers for Ocular Surface Regeneration

    Information
    13 April 2021 219 hit(s) Biomaterials
    Limbal stem cells (LSCs) are already used in cell‐based treatments for ocular surface disorders. Clinical translation of LSCs‐based therapies critically depends on the successful delivery, survival, and retention of these therapeutic cells to the desired region. Such a major bottleneck could be overcome by using an appropriate carrier to provide anchoring sites and structural support to LSC culture and transplantation.
  • Impact of Chemical Composition on the Nanostructure and Biological Activity of α-Galactosidase-Loaded Nanovesicles for Fabry Disease Treatment

    Information
    02 April 2021 234 hit(s) Biomaterials
    Fabry disease is a rare lysosomal storage disorder characterized by a deficiency of α-galactosidase A (GLA), a lysosomal hydrolase. The enzyme replacement therapy administering naked GLA shows several drawbacks including poor biodistribution, limited efficacy, and relatively high immunogenicity in Fabry patients.An attractive strategy to overcome these problems is the use of nanocarriers for encapsulating the enzyme. Nanoliposomes functionalized with RGD peptide have already emerged as a good platform to protect and deliver GLA to endothelial cells.
  • Radiolabeled Cobaltabis(dicarbollide) Anion–Graphene Oxide Nanocomposites for In Vivo Bioimaging and Boron Delivery

    Information
    23 March 2021 264 hit(s) Biomaterials
    A carbon-based hybrid nanocomposite, which consists of monoiodinated boron-cluster derivatives covalently attached to graphene oxide, is hereby introduced. This GO-I-COSAN has been synthesized using a novel boron-rich cobaltabis(dicarbollide) precursor with one iodide group attached to one of the boron atoms of the cluster (I-COSAN) and designed to be subsequently labeled with radioactive 124I for its use in positron emission tomography (PET).
  • Characterization of crystalline forms of gaxilose, a diagnostic drug

    Information
    17 March 2021 258 hit(s) Biomaterials
    Lactose intolerance is a pathology caused by lactase enzyme deficiency, usually produced in the intestinal cells provoking symptoms as abdominal pain, bloating, diarrhea, gas and nausea. Gaxilose, 4-O-β-D galactopyranosyl-d-xylose, is used as a diagnostic drug for a non-invasive method for hypolactasia diagnosis.

INSTITUT DE CIÈNCIA DE MATERIALS DE BARCELONA, Copyright © 2020 ICMAB-CSIC | Privacy Policy | This email address is being protected from spambots. You need JavaScript enabled to view it.